1. Home
  2. NKTR vs SCD Comparison

NKTR vs SCD Comparison

Compare NKTR & SCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • SCD
  • Stock Information
  • Founded
  • NKTR 1990
  • SCD 2003
  • Country
  • NKTR United States
  • SCD United States
  • Employees
  • NKTR N/A
  • SCD N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • SCD Trusts Except Educational Religious and Charitable
  • Sector
  • NKTR Health Care
  • SCD Finance
  • Exchange
  • NKTR Nasdaq
  • SCD Nasdaq
  • Market Cap
  • NKTR 238.7M
  • SCD 259.3M
  • IPO Year
  • NKTR 1994
  • SCD N/A
  • Fundamental
  • Price
  • NKTR $1.35
  • SCD $17.73
  • Analyst Decision
  • NKTR Buy
  • SCD
  • Analyst Count
  • NKTR 4
  • SCD 0
  • Target Price
  • NKTR $2.50
  • SCD N/A
  • AVG Volume (30 Days)
  • NKTR 982.8K
  • SCD 62.6K
  • Earning Date
  • NKTR 11-05-2024
  • SCD 01-01-0001
  • Dividend Yield
  • NKTR N/A
  • SCD 9.63%
  • EPS Growth
  • NKTR N/A
  • SCD N/A
  • EPS
  • NKTR N/A
  • SCD N/A
  • Revenue
  • NKTR $93,157,000.00
  • SCD N/A
  • Revenue This Year
  • NKTR N/A
  • SCD N/A
  • Revenue Next Year
  • NKTR N/A
  • SCD N/A
  • P/E Ratio
  • NKTR N/A
  • SCD N/A
  • Revenue Growth
  • NKTR 6.17
  • SCD N/A
  • 52 Week Low
  • NKTR $0.41
  • SCD $11.33
  • 52 Week High
  • NKTR $1.93
  • SCD $15.87
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 58.23
  • SCD 67.77
  • Support Level
  • NKTR $1.11
  • SCD $17.36
  • Resistance Level
  • NKTR $1.39
  • SCD $17.96
  • Average True Range (ATR)
  • NKTR 0.09
  • SCD 0.36
  • MACD
  • NKTR 0.01
  • SCD 0.02
  • Stochastic Oscillator
  • NKTR 85.71
  • SCD 87.78

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

About SCD LMP Capital and Income Fund Inc.

Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships.

Share on Social Networks: